Larotaxel
Larotaxel: An Experimental Taxane Drug[edit | edit source]
Larotaxel (also known by its code names XRP9881 and RPR109881) is a chemotherapeutic agent that belongs to the taxane class of drugs. Derived and refined for potential antineoplastic applications, Larotaxel showcases the characteristic mechanisms and properties inherent to taxanes, with a unique chemical profile distinguishing it from its contemporaries.
Taxane Class Overview[edit | edit source]
Taxanes are a class of diterpenes originally isolated from the bark of the Pacific yew tree, Taxus brevifolia. Their chemotherapeutic properties are primarily based on their ability to:
- Stabilize microtubule polymers.
- Prevent depolymerization, hindering cell division and proliferation[1].
Prominent members of the taxane class include:
- Paclitaxel (Taxol): The pioneering taxane drug with significant clinical efficacy[2].
- Docetaxel (Taxotere): A semi-synthetic analogue of paclitaxel with an improved efficacy-toxicity ratio in certain cancers[3].
Larotaxel: Distinct Features[edit | edit source]
Distinct from paclitaxel and docetaxel, Larotaxel boasts a specific chemical structure that may result in a unique pharmacodynamic and pharmacokinetic profile. However, as with many experimental drugs, extensive research is pivotal to elucidate the spectrum of its antitumor activities and potential side effects[4].
Clinical Evaluation & Applications[edit | edit source]
Larotaxel has been subjected to experimental evaluations for its:
- Mechanism of action in cell lines.
- Efficacy in various tumor models.
- Safety and tolerability in early-phase clinical trials.
Though its precise position in oncological therapeutics has not been fully established, preliminary investigations suggest potential utility in a spectrum of malignancies resistant to other taxane therapies[5].
Conclusion[edit | edit source]
Larotaxel encapsulates the ongoing efforts of researchers to optimize the therapeutic potential of taxanes, aiming to overcome the limitations of the first-generation agents. While it remains under investigation, Larotaxel's unique profile underscores the dynamic and evolving landscape of oncology drug development.
References[edit | edit source]
- ↑ Horwitz, S.B. (1994). Mechanism of action of taxol. Trends in Pharmacological Sciences, 15(5), 134-136.
- ↑ Rowinsky, E.K., et al. (1990). Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. Journal of Clinical Oncology, 8(12), 2010-2025.
- ↑ Tannock, I.F., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine, 351(15), 1502-1512.
- ↑ Bissery, M.C., et al. (1995). Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Research, 55(11), 2325-2333.
- ↑ Vrignaud, P., et al. (1998). Preclinical profile of XRP9881 (RPR 109881A), a novel taxane, and its activity in taxane-resistant cell lines. Anti-Cancer Drugs, 9(9), 759-771.
Larotaxel Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Admin, Prab R. Tumpati, MD